VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2
Study sponsor: Inovio Pharmaceuticals
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2020-06-16Actual
Enrollment · participants23Actual
Source updated2023-07-14Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.